Brian Sullivan discussed the FDA approval of REVTORPYK, involving researchers from Fred Hutchinson and the University of Washington.

The entities involved

• FDA →
  • NRx Pharmaceuticals is undergoing a first-cycle review of an ANDA for ketamine, noting its strategic importance for the U.S. military and VA.19:54
  • BridgeBio announced on August 14, 2026, that it has submitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA).17:22
• Fred Hutchinson Cancer Center →

  cancer research institute in Seattle, Washington, United States

  Nothing else this week.

• University of Washington →

  public research university in Seattle, Washington, United States

  • Horacio de la Iglesia has been identified as a professor of biology at the University of Washington.Sat 14:15
  • Facts established on August 3rd regarding the locations and affiliations of various entities, including the University of Washington, Seattle, the Pacific Northwest, KFI, and the school system.Sat 13:26

Related events

• FDA approved a new cancer drug in Massachusetts on October 21, 2026.Oct 22
• FDA approved a medical device from Abbott and supported a PARADIGM study based on data from the Cleveland Clinic.Wed 21:06
• The FDA approved GSK's Jemperli drug, while Memorial Sloan Kettering Cancer Center was involved in the AZUR-1 trial.Oct 19
• Research advances have led to the approval of new therapies by the FDA.Oct 15
• FDA approval expands patient access to therapies for ACCORD.Jul 10